This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

Biotech and pharmaceutical companies opened the week with clinical, legal, financial and structural updates, and stocks moved accordingly in both directions, luring indices to dabble a bit in the red.

Sanofi-Aventis (SNY - Get Report) gave the most comprehensive update on Monday saying it intends to make 31 submissions for new drugs by the end of 2010, and that it has 48 drugs in late-stage development.

The pharmaceutical and human vaccine company also said its xaliproden treatment for Alzheimer's disease didn't demonstrate a statistically significant effect in late-stage studies and thus will be discontinued. But Sanofi expects to file its antidepressant saredutant, which was effective in two late-stage trials, for marketing approval in the U.S. and Europe in 2008. Also, another antidepressant, amibergon, met its target in one of four studies and the company expects to assess its complete efficacy data in the next year.

Sanofi also plans to refile its marketing application for obesity drug Acomplia (Zimulti) in the U.S. pending long-term late-stage trial data expected in 2010. The drug, which is already available in Europe, was rejected by the Food and Drug Administration earlier this year when regulators questioned its psychological side effects. Sanofi shares fell 98 cents, or 2.3%, to $41.70.

In a smaller update, Schering-Plough (SGP) said Monday that it initiated two large phase III clinical studies with vicriviroc, for adults with HIV who have only the R5-type virus and who have already tried another treatment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CELG $113.47 -2.48%
DEPO $25.97 -4.03%
ENMD $1.18 1.72%
JNJ $99.58 -0.21%
SNY $51.68 -0.88%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs